Interleukin-1β in innate inflammation, autophagy and immunity
- PMID: 24275601
- DOI: 10.1016/j.smim.2013.10.018
Interleukin-1β in innate inflammation, autophagy and immunity
Abstract
Although IL-1β is the master inflammatory cytokine in the IL-1 family, after more than ten years of continuous breeding, mice deficient in IL-1β exhibit no spontaneous disease. Therefore, one concludes that IL-1β is not needed for homeostasis. However, IL-1β-deficient mice are protected against local and systemic inflammation due to live infections, autoimmune processes, tumor metastasis and even chemical carcinogenesis. Based on a large number of preclinical studies, blocking IL-1β activity in humans with a broad spectrum of inflammatory conditions has reduced disease severity and for many, has lifted the burden of disease. Rare and common diseases are controlled by blocking IL-1β. Immunologically, IL-1β is a natural adjuvant for responses to antigen. Alone, IL-1β is not a growth factor for lymphocytes; rather in antigen activated immunocompetent cells, blocking IL-1 reduces IL-17 production. IL-1β markedly increases in the expansion of naive and memory CD4T cells in response to challenge with their cognate antigen. The response occurs when only specific CD4T cells respond to IL-1β and not to IL-6 or CD-28. A role for autophagy in production of IL-1β has emerged with deletion of the autophagy gene ATG16L1. Macrophages from ATG16L1-deficient mice produce higher levels of IL-1β after stimulation with TLR4 ligands via a mechanism of caspase-1 activation. The implications for increased IL-1β release in persons with defective autophagy may have clinical importance for disease.
Keywords: Autophagy; Caspase-1-independent; Innate inflammation; Interleukin-1β.
Copyright © 2013. Published by Elsevier Ltd.
Similar articles
-
Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2.Gut. 2011 Sep;60(9):1229-35. doi: 10.1136/gut.2010.228908. Epub 2011 Mar 15. Gut. 2011. PMID: 21406388
-
Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice.Immunol Lett. 2009 Apr 27;123(2):138-43. doi: 10.1016/j.imlet.2009.03.004. Epub 2009 Mar 21. Immunol Lett. 2009. PMID: 19428561
-
Interleukin 17 (IL-17) increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1beta and IL-6 production in autoimmune arthritis.J Rheumatol. 2009 Apr;36(4):684-92. doi: 10.3899/jrheum.080169. Epub 2009 Feb 17. J Rheumatol. 2009. PMID: 19228664
-
Treating inflammation by blocking interleukin-1 in humans.Semin Immunol. 2013 Dec 15;25(6):469-84. doi: 10.1016/j.smim.2013.10.008. Epub 2013 Nov 23. Semin Immunol. 2013. PMID: 24275598 Free PMC article. Review.
-
The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.Immunotherapy. 2015;7(3):243-54. doi: 10.2217/imt.14.106. Immunotherapy. 2015. PMID: 25804477 Review.
Cited by
-
Toxoplasma gondii activates a Syk-CARD9-NF-κB signaling axis and gasdermin D-independent release of IL-1β during infection of primary human monocytes.PLoS Pathog. 2019 Aug 26;15(8):e1007923. doi: 10.1371/journal.ppat.1007923. eCollection 2019 Aug. PLoS Pathog. 2019. PMID: 31449558 Free PMC article.
-
Isosteviol Sodium Exerts Anti-Colitic Effects on BALB/c Mice with Dextran Sodium Sulfate-Induced Colitis Through Metabolic Reprogramming and Immune Response Modulation.J Inflamm Res. 2021 Dec 20;14:7107-7130. doi: 10.2147/JIR.S344990. eCollection 2021. J Inflamm Res. 2021. PMID: 34992409 Free PMC article.
-
Severe alcoholic hepatitis-current concepts, diagnosis and treatment options.World J Hepatol. 2014 Oct 27;6(10):688-95. doi: 10.4254/wjh.v6.i10.688. World J Hepatol. 2014. PMID: 25349640 Free PMC article. Review.
-
Simultaneous Inhibition of Three Major Cytokines and Its Therapeutic Effects: A Peptide-Based Novel Therapy against Endotoxemia in Mice.J Pers Med. 2021 May 20;11(5):436. doi: 10.3390/jpm11050436. J Pers Med. 2021. PMID: 34065201 Free PMC article.
-
Endomorphin-2- and Neurotensin- Based Chimeric Peptide Attenuates Airway Inflammation in Mouse Model of Nonallergic Asthma.Int J Mol Sci. 2019 Nov 26;20(23):5935. doi: 10.3390/ijms20235935. Int J Mol Sci. 2019. PMID: 31779093 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources